1. Scrip
  2. >>Business

2Q Pharma Results Preview: Bristol, AstraZeneca, Roche, Celgene, Bayer, Merck, AbbVie & Sanofi

 
• By Emily Hayes, Lucie Ellis-Taitt, Lubna Ahmed, Kevin Grogan, Joseph Haas, and Mandy Jackson

PD-1 inhibitor performance and the intense curiosity around AstraZeneca both for its MYSTIC trial and Soriot's faithfulness to the company are key themes at the half-year mark. Eyes are also on commercial performance for Roche's Ocrevus and Merck's anacetrapib for clarity on whether it has a commercial future.

Binoculars
Watching for pharma's Q2 ships to come in • Source: Shutterstock

Bristol-Myers Squibb Co.'s PD-1 inhibitor Opdivo has enjoyed spectacular sales since entering the market in December 2014, and now the challenge is to retain its position.

In NSCLC, Opdivo (nivolumab) is approved for second-line but not first-line treatment. During the first quarter, the drug brought in strong sales of $1.1bn, despite facing new competition from Roche's PD-L1 inhibitor Tecentriq in second-line NSCLC. (Also see "Bristol's New CSO Lynch Defends Lung Cancer Plans, Proclaims R&D Priorities" - Scrip, 27 April, 2017.) And Merck & Co. Inc

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Earnings

More from Business

Roche Reveals Another US Manufacturing Site As Tariff Pressures Seem To Ease

 
• By Mandy Jackson

Roche/Genentech unveiled plans for a $700m-plus manufacturing facility for weight loss drugs in North Carolina as President Trump signaled such investments could mean no tariffs for pharma.

Trump’s MFN Executive Order More Rhetoric Than Action

 
• By Jessica Merrill

The details of Trump’s latest executive order on drug pricing are vague and the president put more blame on other countries and pharma distributors than drug companies.

Biopharma Deals ROI Has Fallen And Market Instability Could Make It Worse

 
• By Andrew McConaghie

Rising biotech valuations mean return on investment on some deals is non-existent for big pharma, though certain strategies will improve chances of success, a new analysis has found.